CCCC Q2 2023 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-80.7% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$38M-1410.2% margin

Net Income

-$36M-1348.4% margin

EPS (Diluted)

$-0.73

QoQ Revenue Growth

-29.1%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$375M

Total Liabilities

$141M

Stockholders' Equity

$234M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$14M	-80.7%
Gross Profit	$3M	-$17M	+115.2%
Operating Income	-$38M	-$27M	-37.2%
Net Income	-$36M	-$27M	-31.0%